Sept 28 (Reuters) - Aurinia Pharmaceuticals Inc AUP.TO :
* AURINIA COMPLETES FINAL PATIENT TREATMENT IN AUDREY PHASE 2/3 CLINICAL TRIAL OF VOCLOSPORIN OPHTHALMIC SOLUTION FOR DRY EYE SYNDROME
* AURINIA PHARMACEUTICALS INC - VOCLOSPORIN OPHTHALMIC SOLUTION (VOS) RESULTS ON TRACK TO BE REPORTED IN Q4 OF 2020